10634162

=> d his

```
     (FILE 'HOME' ENTERED AT 10:28:34 ON 02 JUL 2004)

     FILE 'REGISTRY' ENTERED AT 10:28:47 ON 02 JUL 2004
L1                STRUCTURE UPLOADED
L2              6 S L1
L3                STRUCTURE UPLOADED
L4              1 S L3
L5                STRUCTURE UPLOADED
L6              1 S L5
L7                STRUCTURE UPLOADED
L8             50 S L7
L9                STRUCTURE UPLOADED
L10            41 S L9
L11               STRUCTURE UPLOADED
L12            14 S L11
L13           299 S L11 SSS FULL

     FILE 'CAPLUS' ENTERED AT 11:27:22 ON 02 JUL 2004
L14            69 S L13
L15            41 S L14 AND PATENT/DT
L16             9 S L15 AND THIENOPYRIDI?
                  E WILSON MICHAEL WILLIAM/IN
L17            21 S E2-E4
L18             0 S L17 AND L14
L19             0 S L17 AND L15
L20             5 S L17 AND BICYCLIC
L21             5 S L20 AND METALLOPROTEINASE
                  SELECT L21 5 RN

     FILE 'REGISTRY' ENTERED AT 11:35:21 ON 02 JUL 2004
L22            56 S E1-E56
L23               STRUCTURE UPLOADED
L24             0 S L23  SUB=L13 SAMPLE
L25             0 S L23
L26             1 S L23 SSS FULL SUB=L13

     FILE 'CAPLUS' ENTERED AT 11:40:22 ON 02 JUL 2004
L27             1 S L26
L28               STRUCTURE UPLOADED
                  S L28

     FILE 'REGISTRY' ENTERED AT 11:53:09 ON 02 JUL 2004
L29             5 S L28

     FILE 'CAPLUS' ENTERED AT 11:53:10 ON 02 JUL 2004
L30             4 S L29

     FILE 'REGISTRY' ENTERED AT 11:53:33 ON 02 JUL 2004
L31            86 S L28 SSS FULL

     FILE 'CAPLUS' ENTERED AT 11:55:07 ON 02 JUL 2004
L32            22 S L31
```

C:\STNEXP4\QUERIES\10634162bb.str



chain nodes :
11 14 15 16 17 18 19 20 25 27 28 29
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
4-27 5-28 8-11 14-15 14-18 16-17 17-19 20-25 28-29
ring bonds :
1-6 1-2 2-7 2-3 3-9 3-4 4-5 5-6 7-8 8-9
exact/norm bonds :
1-6 1-2 2-7 2-3 3-9 3-4 4-5 4-27 5-6 5-28 7-8 8-9 8-11 14-15 14-18 16-17
17-19 20-25 28-29
isolated ring systems :
containing 1 :

G3:C,S,N

G4:CH3,Et,n-Pr,Cy,[*1],[*2],[*3]

G5:C,O,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:CLASS 14:CLASS
15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 25:CLASS 27:CLASS 28:CLASS
29:CLASS

C:\STNEXP4\QUERIES\10634162aaa.str



chain nodes :
11 14 15 16 17 18 19 20 25 27 28 29
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
4-27 5-28 8-11 14-15 14-18 16-17 17-19 20-25 28-29
ring bonds :
1-6 1-2 2-7 2-3 3-9 3-4 4-5 5-6 7-8 8-9
exact/norm bonds :
1-6 1-2 2-7 2-3 3-9 3-4 4-5 4-27 5-6 5-28 7-8 8-9 8-11 14-15 14-18 16-17
17-19 20-25 28-29
isolated ring systems :
containing 1 :

G3:C,S,N

G4:CH3,Et,n-Pr,Cy,[*1],[*2],[*3]

G5:C,O,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:CLASS 14:CLASS
15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 25:CLASS 27:CLASS 28:CLASS
29:CLASS

C:\STNEXP4\QUERIES\10634162aa.str



chain nodes :
11 14 15 16 17 18 19 20 25 27
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
4-27 8-11 14-15 14-18 16-17 17-19 20-25
ring bonds :
1-6 1-2 2-7 2-3 3-9 3-4 4-5 5-6 7-8 8-9
exact/norm bonds :
1-6 1-2 2-7 2-3 3-9 3-4 4-5 4-27 5-6 7-8 8-9 8-11 14-15 14-18 16-17 17-19
20-25
isolated ring systems :
containing 1 :

G3:C,S,N

G4:CH3,Et,n-Pr,Cy,[*1],[*2],[*3]

G5:C,O,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:CLASS 14:CLASS
15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 25:CLASS 27:CLASS

10634162

> d bib abs hitstr

L27 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1975:547414 CAPLUS
DN 83:147414
TI Heterocycles. CXXVII. Action of sulfur on some heterocyclic compounds. Formation of thioamides, oxidative cyclization and thiation
AU Kramberger, L.; Lorencak, P.; Polanc, S.; Vercek, B.; Stanovnik, B.; Tisler, M.; Povazanec, F.
CS Dep. Chem., Univ. Ljubljana, Ljubljana, Yugoslavia
SO Journal of Heterocyclic Chemistry (1975), 12(2), 337-42
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 83:147414
GI For diagram(s), see printed CA Issue.
AB The formation of heterocyclic thioamides from alkylpyridines, heteroarom. amines and sulfur was investigated. Oxidative cyclization of these thioamides afforded the corresponding thiazoloazines. Attempted thiation of some hydrazones gave triazolopyridines and some examples of direct thiation of heterocycles are given. Thus, 2-methylpyridine, 5, and RNH2 gave 10 I (R = 3-pyridyl, 4-pyridyl, 4-methyl-2-pyridyl, 5-methyl-2-pyridyl, 2-pyridazyl, 2-pyrazyl, 2-triazolyl, 5-tetrazolyl, 2-benzothiazolyl, anilino). Oxidative cyclization of I (R = 5-methyl-2-pyridyl) gave II. Attempted thiation of III gave IV and thiation of 2-(N-2-pyridylformimidoyl)pyridine gave I (R = 2-pyridyl).
IT **57036-77-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 57036-77-8 CAPLUS
CN Thiazolo[4,5-b]pyridine, 6-methyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



10634162

=> d 1-22 bib abs hitstr

L32 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:142958 CAPLUS
DN 140:193096
TI Fused bicyclic metalloproteinase inhibitors, pharmaceutical compositions, and therapeutic use
IN Wilson, Michael William
PA Warner-Lambert Company LLC, USA
SO PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014375	A2	20040219	WO 2003-IB3523	20030804
	WO 2004014375	A3	20040603		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-403008P P 20020813
OS MARPAT 140:193096
GI

this app'n



I

AB The invention discloses fused bicyclic metalloproteinase inhibitors I [A = C2-6 alkynyl, bond, etc.; X, Y = O, S, etc. (with proviso); dashed lines = optional double bonds; B = substituted pyridinyl; R1 = C1-6 alkyl, C2-6 alkenyl, etc.], as well as pharmaceutical compns. and methods of treating arthritis, inflammation, cancer and other disorders.

IT **660815-88-3 660815-89-4 660815-90-7**
660815-91-8 660815-92-9 660815-93-0
660816-11-5 660816-12-6 660816-13-7
660816-14-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fused bicyclic metalloproteinase inhibitors, pharmaceutical compns., and therapeutic use)

RN 660815-88-3 CAPLUS
CN Benzoic acid, 4-[[2-[[[(2-methoxy-4-pyridinyl)methyl]amino]carbonyl]thiazolo[5,4-b]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 660815-89-4 CAPLUS
CN Benzoic acid, 4-[[2-[[(phenylmethyl)amino]carbonyl]thiazolo[5,4-b]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 660815-90-7 CAPLUS
CN Thiazolo[5,4-b]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 660815-91-8 CAPLUS
CN Benzoic acid, 4-[[2-[[(phenylmethyl)amino]carbonyl]thieno[2,3-b]pyridin-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 660815-92-9 CAPLUS
CN Benzoic acid, 4-[[2-[[(4-pyridinylmethyl)amino]carbonyl]thieno[2,3-b]pyridin-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 660815-93-0 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 5-[(3,4-difluorophenyl)methyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 660816-11-5 CAPLUS
CN Benzoic acid, 4-[[2-(3-phenyl-1-propynyl)thiazolo[5,4-b]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 660816-12-6 CAPLUS
CN Thiazolo[5,4-b]pyridine, 6-[(3,4-difluorophenyl)methyl]-2-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)



RN 660816-13-7 CAPLUS
CN Benzoic acid, 4-[[2-(3-phenyl-1-propynyl)thieno[2,3-b]pyridin-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 660816-14-8 CAPLUS
CN Thieno[2,3-b]pyridine, 5-[(3,4-difluorophenyl)methyl]-2-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)



L32 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:142808 CAPLUS
DN 140:193094
TI Fused bicyclic metalloproteinase inhibitors, pharmaceutical compositions, and therapeutic use
IN Wilson, Michael William
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004034054	A1	20040219	US 2003-634162	20030805
PRAI	US 2002-403008P	P	20020813		

OS MARPAT 140:193094
GI



I

AB The invention discloses fused bicyclic metalloproteinase inhibitors I [A = C2-6 alkynyl, bond, etc.; X, Y = O, S, etc. (with proviso); dashed lines =

optional double bonds; B = substituted pyridinyl; R1 = C1-6 alkyl, C2-6 alkenyl, etc.], as well as pharmaceutical compns. and methods of treating arthritis, inflammation, cancer, and other disorders.

IT **660815-88-3 660815-89-4 660815-90-7 660815-91-8 660815-92-9 660815-93-0 660816-11-5 660816-12-6 660816-13-7 660816-14-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fused bicyclic metalloproteinase inhibitors, pharmaceutical compns., and therapeutic use)

RN 660815-88-3 CAPLUS
CN Benzoic acid, 4-[[2-[[[(2-methoxy-4-pyridinyl)methyl]amino]carbonyl]thiazolo[5,4-b]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 660815-89-4 CAPLUS
CN Benzoic acid, 4-[[2-[[(phenylmethyl)amino]carbonyl]thiazolo[5,4-b]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 660815-90-7 CAPLUS
CN Thiazolo[5,4-b]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 660815-91-8 CAPLUS
CN Benzoic acid, 4-[[2-[[(phenylmethyl)amino]carbonyl]thieno[2,3-b]pyridin-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 660815-92-9 CAPLUS
CN Benzoic acid, 4-[[2-[[(4-pyridinylmethyl)amino]carbonyl]thieno[2,3-b]pyridin-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 660815-93-0 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 5-[(3,4-difluorophenyl)methyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 660816-11-5 CAPLUS
CN Benzoic acid, 4-[[2-(3-phenyl-1-propynyl)thiazolo[5,4-b]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 660816-12-6 CAPLUS
CN Thiazolo[5,4-b]pyridine, 6-[(3,4-difluorophenyl)methyl]-2-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)



RN 660816-13-7 CAPLUS
CN Benzoic acid, 4-[[2-(3-phenyl-1-propynyl)thieno[2,3-b]pyridin-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 660816-14-8 CAPLUS
CN Thieno[2,3-b]pyridine, 5-[(3,4-difluorophenyl)methyl]-2-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)



L32 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:837084 CAPLUS
DN 139:337959
TI Preparation of nitrogen-containing bicyclic heterocycles for use as antibacterials
IN Brooks, Gerald; Davies, David Thomas; Jones, Graham Elgin; Markwell, Roger Edward; Pearson, Neil David
PA Smithkline Beecham P.L.C., UK
SO PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003087098	A1	20031023	WO 2002-EP5708	20020524
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1399443	A1	20040324	EP 2002-807202	20020524
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	GB 2001-12834	A	20010525		
	WO 2002-EP5708	W	20020524		

OS MARPAT 139:337959
GI



I



II

AB Naphthyridines I [one of Z1-Z5 = N, one = (un)substituted Ch, the others = CH; one of Z1-Z5 = (un)substituted Ch, the others = CH; R1 = H, OH, halogen, (un)substituted alkoxy, alkyl, alkylthio, CF3, NO2, N3, acyl, acyloxy, acylthio, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, amino; R2 = H, (un)substituted alkyl, alkenyl; R3 = H, CO2H, alkoxycarbonyl, (un)substituted alkyl, CONH2, CN, tetrazolyl, 2-oxooxazolidinyl, 3-hydroxy-3-cyclobutene-1,2-dion-4-yl,2,4-thiazolidinedion-5-yl, 1,2,4-triazol-5-yl, 5-oxo-1,2,4-oxadiazol-3-yl; R4 = (un)substituted alkyl, heterocyclic; R5, R6 = H; R5R6 = bond; AB = (un)substituted CONH, NHCO, COCH2, CH2CO, OCH2, CH2O, NHCH2, CH2NH, NHSO2, CH2SO2, CH2CH2; n = 0, 1] were prepared for use as bactericides. Thus, 2,1,3-benzothiadiazole-5-carboxylic acid was reduced to the alc., mesylated, and treated with the amine fragment, prepared from 5-amino-2-methoxypyridine in 5 steps, to give the naphthyridine II, which had IC50 against Staphyloccus aureus Oxford, several S. pneumoniae strains, and Echerichia coli strains of ≤ 4 μg/mL.

IT **615567-85-6P**

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrogen-containing bicyclic heterocycles for use as antibacterials)

RN 615567-85-6 CAPLUS

CN Cyclohexanecarboxamide, 1-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-4-[[(2-methylthiazolo[5,4-b]pyridin-6-yl)methyl]amino]-, dihydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:416457 CAPLUS

DN 139:197453

TI Synthesis of new pyrido [3',2':4,5]thieno[2,3-e]pyrrolo[1,2-α]pyrazines

AU Aadil, Mina; Kirsch, Gilbert

CS Laboratoire de Chimie Bioorganique et Analytique, Faculte des Sciences et Techniques, Mohammedia, Morocco

SO Heterocyclic Communications (2003), 9(2), 123-127
CODEN: HCOMEX; ISSN: 0793-0283

PB Freund Publishing House Ltd.

DT Journal

LA English

OS CASREACT 139:197453

AB The aim of the present paper is to describe the synthesis of several unknown polyfused heterocycles containing the pyrazine ring. Novel pyrido[3',2':4,5]thieno[2,3-e]pyrrolo[1,2-a]pyrazines derivs. have been synthesized starting from Me 3-amino thieno[2,3-b] pyridines carboxylates via a Curtius rearrangement.

IT **582289-74-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrido[3',2':4,5]thieno[2,3-e]pyrrolo[1,2-α]pyrazines via Curtius rearrangement of Me 3-amino-thieno[2,3-b]pyridines carboxylates)

RN 582289-74-5 CAPLUS

CN Thieno[2,3-b]pyridine-2-carbonyl azide, 4-ethyl-5-methyl-3-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10634162

L32 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:264873 CAPLUS
DN 136:304061
TI Bicyclic thiophenes and pharmaceutical compositions containing them as TNF-α formation inhibitors
IN Fujita, Shoichi; Hirayama, Tetsuya; Kawahara, Yoshikazu
PA Nikken Chemicals Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2002105081	A2	20020410	JP 2001-224397	20010725
PRAI JP 2000-229195	A	20000728		

OS MARPAT 136:304061
GI



I

AB The compns., useful for prevention and treatment of inflammation, etc., contain bicyclic thiophenes I [A1 = (un)substituted N-containing heteroaryl; A2 = (un)substituted aryl, (un)substituted cycloalkyl; R1, R2 = (un)substituted lower alkyl, (un)substituted acyl(oxy), etc.; m, n = 0-2; Q1-Q4 = C, CH, CH2, CO, O, N, NH; 1 or 2 of Q1-Q4 = N, NH], their stereoisomers, or salts. 3-Aminocarbonyl-4-(4-fluorophenyl)-5-(4-pyridyl)-2-thiopheneamine was condensed with acetyl chloride and cyclized to give 5-(4-fluorophenyl)-2-methyl-6-(4-pyridyl)thieno[2,3-d]pyrimidin-4(3H)-one, which was orally administered to rats at 50 mg/kg to show 94.0% inhibition of TNF-α formation.
IT **409059-52-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceuticals containing bicyclic thiophenes as TNF-α formation inhibitors)
RN 409059-52-5 CAPLUS
CN Thieno[2,3-b]pyridine, 6-chloro-5-(2-chloroethyl)-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L32 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:740125 CAPLUS
DN 128:16433
TI Preparation of thienopyridininones as GNRH agonists and antagonists
IN Suzuki, Nobuhiro; Furuya, Shuichi
PA Furuya, Shuichi, Japan; Takeda Chemical Industries, Ltd.; Suzuki, Nobuhiro
SO PCT Int. Appl., 285 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 9740846	A1	19971106	WO 1997-JP1459	19970425
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2250908	AA	19971106	CA 1997-2250908	19970425
	AU 9724079	A1	19971119	AU 1997-24079	19970425
	JP 10045625	A2	19980217	JP 1997-108713	19970425
	EP 906115	A1	19990407	EP 1997-919703	19970425
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 6015789	A	20000118	US 1997-894317	19970814
PRAI	JP 1996-109790		19960430		
	JP 1996-138873		19960531		
	WO 1997-JP1459		19970425		

OS MARPAT 128:16433

AB The present invention relates to a pharmaceutical comprising a LH releasing hormone agonist in combination with a LH releasing hormone antagonist. By using a LH releasing hormone agonist and a LH releasing hormone antagonist in combination, the transient exacerbation with elevation of serum testosterone and estrogen owing to the pituitary-gonadotropic action (acute action) manifested immediately following an initial dose of the LH releasing hormone agonist can be successfully obviated. The synthesis of the title compds. and their activity are described.

IT **174072-83-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of condensed bicyclic LHRH antagonists and use in combination with LHRH active peptides)

RN 174072-83-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-methanol, 4-hydroxy-2-(4-methoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)



L32 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1997:552637 CAPLUS

DN 127:149139

TI Preparation of bactericidal pyridothienyl- and pyridofuryloxazolidinones

IN Riedl, Bernd; Haebich, Dieter; Stolle, Andreas; Ruppelt, Martin; Bartel, Stefan; Guarnieri, Walter; Endermann, Rainer; Kroll, Hein-Peter

PA Bayer A.-G., Germany

SO Ger. Offen., 28 pp.
CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

PI	DE 19601264	A1	19970717	DE 1996-19601264	19960116
	EP 785200	A2	19970723	EP 1997-100025	19970103
	EP 785200	A3	19990210		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AU 9710098	A1	19970724	AU 1997-10098	19970109
	US 5827857	A	19981027	US 1997-781001	19970109
	CA 2194938	AA	19970717	CA 1997-2194938	19970113
	JP 09194482	A2	19970729	JP 1997-17559	19970114
	NO 9700175	A	19970717	NO 1997-175	19970115
	ZA 9700303	A	19970717	ZA 1997-303	19970115
	CN 1161968	A	19971015	CN 1997-101806	19970116
	BR 9700702	A	19980901	BR 1997-702	19970116

10634162

PRAI DE 1996-19601264 A 19960116
OS MARPAT 127:149139
GI



I II

AB Title compds. I [R = pyridothienyl, pyridofuryl; R1 = N3, (un)substituted OH, NH2] were prepared Thus, 2-chloro-6-methylpyridine-3-carebonitrile was treated with HSCH2CO2Me to give Me 3-amino-6-methylthieno[2,3-b]pyridine-2-carboxylate, which was deaminated, and converted to the 2-butoxycarbonylamino derivative via the acid azide. 2-Butoxycarbonylamino-6-methylthieno[2,3-b]pyridine was cyclized with (R)-glycidyl butyrate to give the oxazolidinone II [R2 = OH]. This was converted to II [R2 = NHCSMe] which had min. inhibitory concns. against several staphylococcus strains of 2 μg/mL.

IT **193400-72-5P 193400-77-0P 193400-78-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bactericidal pyridothienyl- and pyridofuryloxazolidinones)

RN 193400-72-5 CAPLUS
CN Acetamide, N-[[3-(5-methylthieno[2,3-b]pyridin-2-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193400-77-0 CAPLUS
CN Thiourea, N-methyl-N'-[[3-(5-methylthieno[2,3-b]pyridin-2-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193400-78-1 CAPLUS
CN Ethanethioamide, N-[[3-(5-methylthieno[2,3-b]pyridin-2-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **193400-59-8P 193400-62-3P 193400-66-7P**
193400-69-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bactericidal pyridothienyl- and pyridofuryloxazolidinones)

RN 193400-59-8 CAPLUS
CN Carbamic acid, (5-methylthieno[2,3-b]pyridin-2-yl)-, butyl ester (9CI) (CA INDEX NAME)



RN 193400-62-3 CAPLUS
CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(5-methylthieno[2,3-b]pyridin-2-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193400-66-7 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-(5-methylthieno[2,3-b]pyridin-2-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193400-69-0 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-(5-methylthieno[2,3-b]pyridin-2-yl)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L32 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:528659 CAPLUS
DN 127:135807
TI Preparation of condensed bicyclic compounds as prolactin production inhibitors
IN Suzuki, Nobuhiro; Matsumoto, Hirokazu; Furuya, Shuichi
PA Takeda Chemical Industries, Ltd., Japan
SO Eur. Pat. Appl., 149 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 781774	A2	19970702	EP 1996-119589	19961206
	EP 781774	A3	19971112		
	EP 781774	B1	20020731		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CA 2192283	AA	19970609	CA 1996-2192283	19961206
	JP 09216823	A2	19970819	JP 1996-326455	19961206
	AT 221534	E	20020815	AT 1996-119589	19961206
	US 5977132	A	19991102	US 1996-762125	19961209
PRAI	JP 1995-345046	A	19951208		

OS MARPAT 127:135807
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; W = (un)substituted homo or hetero 5-7-membered ring; Y = (un)substituted homo or hetero 5-7-membered ring] and their salts, useful for the prophylaxis or therapy of diseases accompanied with an excess prolactin production or diseases having enhanced reactivity with prolactin, or for inhibiting puerperal lactation, and also useful as a prophylactic or therapeutic agent of galactorrhea, hyperprolactinemic ovulation disturbance, amenorrhea-galactorrhea syndrome, prolactinoma, and interbrain tumor, and acromegaly, pituitary gigantism, were prepared and formulated. Thus, reaction of 4-hydroxy-5-hydroxymethyl-2-(4-methoxyphenyl)-3-methylthieno[2,3-b]pyridine with 2-fluorobenzyl chloride in the presence of KI afforded the title compound II. For example, the title compound III.HCl showed 34% inhibition of the PRL secretion at 2μM and 62% inhibition at 10μM.

IT **174072-83-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of condensed bicyclic compds. as prolactin production inhibitors)
RN 174072-83-4 CAPLUS
CN Thieno[2,3-b]pyridine-5-methanol, 4-hydroxy-2-(4-methoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)



L32 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:381008 CAPLUS
DN 126:343558
TI Preparation of thienopyridine derivatives as gonadotropin releasing hormone antagonists.
IN Furuya, Shuichi; Choh, Nobuo; Harada, Masataka; Sasaki, Satoshi
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9714697	A1	19970424	WO 1996-JP3018	19961018
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9673333	A1	19970507	AU 1996-73333	19961018
	JP 09169767	A2	19970630	JP 1996-275672	19961018
	EP 862573	A1	19980909	EP 1996-935359	19961018
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1200124	A	19981125	CN 1996-197675	19961018
	CN 1063446	B	20010321		
	US 5744479	A	19980428	US 1997-779608	19970107
PRAI	JP 1995-271639	A	19951019		
	WO 1996-JP3018	W	19961018		

OS MARPAT 126:343558
GI



I

AB Title compds. [I; R1, R2 = H, group bonded through a C, N, O, or S atom; R3 = (substituted) (hetero)cyclyl; R4 = (substituted) heterocyclyl, group bonded through a heteroatom; R5 = H, group bonded through a C atom; n = 0-3; with provisos], were prepared Thus, 4,7-dihydro-2-(4-isobutyrylaminophenyl)-3-(N-benzyl-N-methylaminomethyl)-5-hydroxy-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine (preparation given) was stirred with isopropylsulfonyl chloride and Et3N in CH2Cl2 to give 51% 4,7-dihydro-2-(4-isobutyrylaminophenyl)-3-(N-benzyl-N-methylaminomethyl)-5-isopropylsulfonyloxy-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine. The latter showed IC50 = 0.3 nM for inhibition of 125I-leuprolrelin binding to GnRH receptors.

IT **174072-83-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thienopyridine derivs. as gonadotropin releasing hormone antagonists)

RN 174072-83-4 CAPLUS
CN Thieno[2,3-b]pyridine-5-methanol, 4-hydroxy-2-(4-methoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)

10634162



L32 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:456309 CAPLUS
DN 125:221519
TI Synthesis of 3-cyano-5-ethyl-6-methylpyridine-2(1H)-thione and condensed heterocycles based on it
AU Rodinovskaya, L. A.; Shestopalov, A. M.; Belukhina, E. V.; Litvinov, V. P.
CS Inst. Org. Khim. im. Zelinskogo, Moscow, 117913, Russia
SO Khimiya Geterotsiklicheskikh Soedinenii (1996), (6), 851-857
CODEN: KGSSAQ; ISSN: 0132-6244
PB Latviiskii Institut Organicheskogo Sinteza
DT Journal
LA Russian
GI



AB Pyridinethiones I (R1 = Et, R2 = Me; R1 = H, R2 = Pr) were prepared by formylation of 2-pentanone, followed by cyclocondensation with NCCH2CSNH2. Alkylation of I with ClCH2Z (Z = CONH2, COOMe, COOEt, COPh, C15H31, CN) gave (alkylthio)pyridines (II). Conversions of I and II to thienopyridines (III) and pyridothienopyrimidines (IV) were described.
IT **174314-60-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 174314-60-4 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-5-ethyl-6-methyl- (9CI) (CA INDEX NAME)



L32 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:27901 CAPLUS
DN 124:202066
TI Synthesis of 3-cyano-5-ethyl-6-methylpyridine-2(1H)-thione and condensed heterocycles based on it
AU Rodinovskaya, L. A.; Shestopolov, A. M.; Belukhina, E. V.; Litvinov, V. P.
CS Inst. Org. Khim. im. N. D. Zelinskogo, Moscow, Russia
SO Khimiya Geterotsiklicheskikh Soedinenii (1995), (6), 851-7

10634162

CODEN: KGSSAQ; ISSN: 0132-6244
PB Latviiskii Institut Organicheskogo Sinteza
DT Journal
LA Russian
GI


I


II


III


IV

AB Pyridinethiones I (R1 = Et, R2 = Me; R1 = H, R2 = Pr) were prepared by formylation of MeCOPr and reaction of the unsatd. ketones formed with NCCH2CSNH2. Alkylation of I with ClCH2Z (Z = alkyl, carbalkoxy, COPh, CONH2, CN) occurred on the S atom to give II (same R1, R2, Z). II were then converted to thienopyridines (III) and pyridothienopyrimidines (IV).

IT **174314-60-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization with formamide)

RN 174314-60-4 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-5-ethyl-6-methyl- (9CI) (CA INDEX NAME)



L32 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:998353 CAPLUS
DN 124:202226
TI Preparation of thienopyridinones as gonadotropin-releasing hormone antagonists
IN Furuya, Shuichi; Choh, Nobuo; Kato, Koichi; Hinuma, Shuji
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 203 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9528405	A1	19951026	WO 1995-JP728	19950414
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
TW 449600	B	20010811	TW 1995-84103400	19950410
CA 2186124	AA	19951026	CA 1995-2186124	19950414
AU 9522239	A1	19951110	AU 1995-22239	19950414
AU 697472	B2	19981008		
EP 756599	A1	19970205	EP 1995-915318	19950414

EP 756599 B1 20031126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
CN 1146206 A 19970326 CN 1995-192628 19950414
CN 1092197 B 20021009
HU 76320 A2 19970828 HU 1996-2884 19950414
RU 2150470 C1 20000610 RU 1996-120203 19950414
NZ 332206 A 20010629 NZ 1995-332206 19950414
CZ 290713 B6 20020911 CZ 1996-3028 19950414
AT 255113 E 20031215 AT 1995-915318 19950414
JP 08295693 A2 19961112 JP 1995-91068 19950417
BR 9501736 A 19951114 BR 1995-1736 19950419
US 5817819 A 19981006 US 1995-454304 19950616
CA 2211969 AA 19960815 CA 1996-2211969 19960207
WO 9624597 A1 19960815 WO 1996-JP263 19960207
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AZ, BY, KG, KZ, RU, TJ
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
AU 9646327 A1 19960827 AU 1996-46327 19960207
JP 09169768 A2 19970630 JP 1996-21342 19960207
EP 808317 A1 19971126 EP 1996-901958 19960207
EP 808317 B1 20030910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE
CN 1173868 A 19980218 CN 1996-191854 19960207
CN 1064045 B 20010404
BR 9600341 A 19980915 BR 1996-341 19960207
AT 249464 E 20030915 AT 1996-901958 19960207
NO 9604434 A 19961018 NO 1996-4434 19961018
FI 9604195 A 19961217 FI 1996-4195 19961018
AU 9883169 A1 19981105 AU 1998-83169 19980908
AU 713116 B2 19991125
US 6187788 B1 20010213 US 1998-164349 19981001
CZ 290723 B6 20021016 CZ 2000-2915 20000809
US 6514988 B1 20030204 US 2000-672777 20000929
PRAI JP 1994-80732 A 19940419
JP 1994-195541 A 19940819
JP 1994-271010 A 19941104
JP 1995-20717 A 19950208
JP 1995-40151 A 19950228
AU 1995-22239 A3 19950414
NZ 1995-283813 A1 19950414
US 1995-454304 A2 19950414
WO 1995-JP728 W 19950414
JP 1995-91068 A 19950417
JP 1995-271638 A 19951019
WO 1996-JP263 W 19960207
US 1998-164349 A3 19981001
OS MARPAT 124:202226
GI



I

II



III

AB Title compds. [I; R1,R2 = H, C-, N-, or S-attached group (sic); R11 = (CH2)nR3; R3 = homocyclic (sic) or heterocyclic group; Z = CR4:CR5; R4 = H, CHO, (esterified or amidated) CO2H, etc.; R5 = H, C-attached group; n = 0-3] and I [R1 = (CH2)rR13; R2 = (un)substituted aryl; R11 = H, (ar)alkyl, etc.; R13 = (un)substituted amino; Z = NR12CO; R12 = H, alkyl, aryl(alkyl), etc.; r = 0-3] were prepared Thus, 4-(MeO)C6H4CH2COMe was condensed with NCCH2CO2Et and the product treated with S/Et2NH to give Et 2-amino-4-methyl-5-(4-methoxyphenyl)thiophene-3-carboxylate which was N-alkylated by EtOCH:C(CO2Et)2 and the product cyclized to give, after NaH treatment and condensation with 2-(MeO)C6H4CH2Cl, title product II [R = MeO, R3 = C6H4(OMe)-2, R4 = CO2Et]. II [R = NO2, R3 = C6H3F2-2,6, R4 = COPh] was converted in 4 steps to title compound III which gave .apprx.85% reduction of mouse plasma testosterone levels at 30mg/kg/day orally for 3 days.

IT **174072-83-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thienopyridinones as gonadotropin-releasing hormone antagonists)

RN 174072-83-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-methanol, 4-hydroxy-2-(4-methoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)



L32 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1993:671114 CAPLUS

DN 119:271114

TI Synthesis of some new pyrido[3',2':4,5]thieno[3,2-d]1,2,3-triazines with antianaphylactic activity

AU Wagner, G.; Leistner, S.; Vieweg, H.; Krasselt, U.; Prantz, J.

CS Fachbereich Biowiss., Univ. Leipzig, Germany

SO Pharmazie (1993), 48(7), 514-18
CODEN: PHARAT; ISSN: 0031-7144

DT Journal

LA German

GI



I



III

AB Some new pyridothienotriazinones I (R = Me, Ph, 4-ClC6H4, 4-BrC6H4, 2-furyl, 2-naphthyl; R1 = H, Me, CH2Ph, CH2C6H4CN-4; R2 = Ph, Me, 4-ClC6H4, pyridyl, CONH2, CONHBu, CONHCH2CH2OH, piperidinocarbonyl, CO2Et, CO2H, 4-BrC6H4) were synthesized from 2-thioxo-1,2-dihydropyridine-3-carbonitriles (II) via 3-amino-thieno[3,2-b]pyridine-2-carboxamides. II were converted to 3-amino-thieno[2,3-b]pyridine-2-carbonitriles which yielded the pyridothienotriazines III (R = Ph, Me; R1 = H, Me, CH2Ph, CH2C6H4CN-4; R2 = pyridyl, 4-ClC6H4, CONHBu; R3 = piperidino, NHNH2, NHCH2CH2NMe2, NHCH2CH2OH, NHBu, NHCH2CH2NET2, NHCH2C6H4Cl-2) via III (R3 = Cl). I (R-R2 = Me; R = Me, R1 = H, R2 = 3-, 4-pyridyl) and III (R = Me, R1 = H, R2 = CONHBu, R3 = NHBu) showed respectable antianaphylactic activity.

IT **119003-37-1P 119003-38-2P 119003-39-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(reactant in preparation of antianaphylactic pyridothienotriazines)

RN 119003-37-1 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 119003-38-2 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4,6-dimethyl-5-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 119003-39-3 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-5-[(4-cyanophenyl)methyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)



L32 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:101913 CAPLUS
DN 118:101913
TI Synthesis of 2,3-dihydroimidazo[1,2-c]- and 3,4-dihydro-2H-pyrimido[1,2-

c]pyrido[3',2':4,5]thieno[2,3-e]pyrimidines via 4-(ω-hydroxyalkylamino) derivatives of pyridothienopyrimidines. Part 35. Polycyclic azines with heteroatoms in 1- and 3-position

AU Vieweg, H.; Boehm, N.; Krasselt, U.; Leistner, S.; Wagner, G.
CS Sekt. Biowiss., Univ. Leipzig, Germany

SO Pharmazie (1992), 47(10), 751-4
CODEN: PHARAT; ISSN: 0031-7144
DT Journal
LA German

GI



I



II



III

AB Title compds. I (R = Me, Ph, 4-BrC6H4; R1 = H, Me, CH2Ph, CH2C6H4CN-4; R2 = Me, 4-BrC6H4; R3 = H, Me, Ph; n = 1, 2) were prepared from the ketones II via the chlorides III and the hydroxyalkylamines.

IT **119003-37-1 119003-38-2 119003-39-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclization of, with orthoformate)

RN 119003-37-1 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 119003-38-2 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4,6-dimethyl-5-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 119003-39-3 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-5-[(4-cyanophenyl)methyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)



L32 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:80893 CAPLUS
DN 118:80893
TI Synthesis of tetracyclic pyridines from 3-amino-2-(dihydroimidazolyl)- or tetrahydropyrimidinyl)thieno[2,3-b]pyrimidines by introduction of C1- or N1-components. 34. Polycyclic azines with heteroatoms in 1- and 3-position
AU Leistner, S.; Krasselt, U.; Dumke, S.; Wagner, G.
CS Sekt. Biowiss., Univ. Leipzig, Leipzig, O-7010, Germany
SO Pharmazie (1992), 47(9), 682-6
CODEN: PHARAT; ISSN: 0031-7144
DT Journal
LA German
GI



I

AB Previously prepared thienopyridines I (R = NH2, R1 = H; R2 = Me, Ph, 4-BrC6H4; R3 = H, Me; R4 = H, Me, 4-BrC6H4; n = 1, 2) were cyclized with HC(OMe)3 or EtO2CCO2Et to give I (RR1 = N:CH, N:CCO2Et). Treatment of I (R = NH2, R1 = H) with CS2 gave I (RR1 = NHCS), which were S-alkylated or hydrolyzed to I (RR1 = NHCO). I (RR1 = N:N) were obtained from I (R = NH2, R1 = H) and NaNO2.
IT **141278-06-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclization of, with orthoformate)
RN 141278-06-0 CAPLUS
CN Thieno[2,3-b]pyridin-3-amine, 2-(4,5-dihydro-1H-imidazol-2-yl)-4,5,6-trimethyl- (9CI) (CA INDEX NAME)



IT **141278-11-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with orthoformate)
RN 141278-11-7 CAPLUS
CN Thieno[2,3-b]pyridin-3-amine, 4,5,6-trimethyl-2-(1,4,5,6-tetrahydro-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



L32 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:235578 CAPLUS
DN 116:235578
TI Heteroatom-containing polycyclic azines. 31. Synthesis of imidazolin-2-yl- and 3,4,5,6-tetrahydropyrimidin-2-yl-3-aminothieno[2,3-b]pyridines
AU Leistner, S.; Wagner, G.; Krasselt, U.; Dumke, S.
CS Sekt. Biowiss., Univ. Leipzig, Leipzig, O-7010, Germany
SO Pharmazie (1992), 47(1), 11-14
CODEN: PHARAT; ISSN: 0031-7144
DT Journal
LA German
GI



I



II

AB The title compds. I (n = 1, 2; R = Me, Ph, 4-BrC6H4; R1 = H, Me; R2 = H, Me, 4-BrC6H4) were prepared by the reaction of diaminoalkanes and CS2 with the aminothieno[2,3-b]pyridines or cyanomethylthiopyridines, or from aminothieno[2,3-b]pyridinecarbothioamides with diaminoalkanes. The reaction of the aminothienocarboxamides II (R3 = cyano) with diaminoalkanes gave II (R3 = 2-imidazolinyl, 2-tetrahydropyrimidinyl). Compds. with two imidazoline or two tetrahydropyrimidine substituents were similarly synthesized.

IT **141278-06-0P 141278-11-7P 141278-17-3P**
141278-18-4P 141278-19-5P 141278-20-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 141278-06-0 CAPLUS
CN Thieno[2,3-b]pyridin-3-amine, 2-(4,5-dihydro-1H-imidazol-2-yl)-4,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 141278-11-7 CAPLUS
CN Thieno[2,3-b]pyridin-3-amine, 4,5,6-trimethyl-2-(1,4,5,6-tetrahydro-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 141278-17-3 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-5-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)



RN 141278-18-4 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4,6-dimethyl-5-[[4-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 141278-19-5 CAPLUS
CN Thieno[2,3-b]pyridin-3-amine, 2-(4,5-dihydro-1H-imidazol-2-yl)-5-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)



RN 141278-20-8 CAPLUS
CN Thieno[2,3-b]pyridin-3-amine, 4,6-dimethyl-2-(1,4,5,6-tetrahydro-2-pyrimidinyl)-5-[[4-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



IT **119003-39-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with ethylenediamine and carbon disulfide)
RN 119003-39-3 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-5-[(4-cyanophenyl)methyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)



L32 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:151702 CAPLUS
DN 116:151702
TI Multicyclic azines with hetero atom in 1- and 3-positions. 29. Synthesis of pyrido[3',2':4,5]thieno[2,3-e]-1,2,4-triazolo[4,3-c]pyrimidines and the isomeric pyrido[3',2':4,5]thieno[2,3-c]-1,2,4-triazolo[2,3-c]pyrimidines
AU Wagner, G.; Krasselt, U.; Leistner, S.
CS Sekt. Biowiss., Univ. Leipzig, Leipzig, O-7010, Germany
SO Pharmazie (1991), 46(6), 409-12
CODEN: PHARAT; ISSN: 0031-7144
DT Journal
LA German
OS CASREACT 116:151702
GI



I



II

AB The isomeric title compds. I and II and (R1 = R2 = R3 = Me, R4 = H, Me, CO2Et, CH2CO2Et; R1 = R3 = Me, R2 = H, R4 = H, Me; R1 = Ph, R2 = R3 = H, R4 = H, Me) were synthesized. The synthesis of I was achieved by the reaction of the 4-hydrazinopyrimidine derivs. with HC(OEt)3/Ac2O, Ac2O, di-Et oxalate and di-Et malonate, resp. I were transformed to the thermodynamically more stable II. The condensed pyrimidines II were also synthesized by the reaction of the 3-amino-2-iminopyrimidine derivs. or the 4-hydrazinopyrimidine derivs. with different C-1 components.
IT **119003-37-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with tri-Et orthoformate)
RN 119003-37-1 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4,5,6-trimethyl- (9CI) (CA INDEX NAME)



L32 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:632279 CAPLUS
DN 115:232279
TI Preparation of 7-(biphenylmethyl)-4-oxothieno[2,3-b]pyrimidine-5-carboxylates as angiotensin II antagonists
IN Morimoto, Akira; Nishikawa, Kohei; Naka, Takehiko
PA Takeda Chemical Industries, Ltd., Japan
SO Eur. Pat. Appl., 47 pp.

10634162

CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 443568	A1	19910828	EP 1991-102513	19910221
	EP 443568	B1	19960612		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2036618	AA	19910823	CA 1991-2036618	19910219
	CA 2036618	C	20021029		
	JP 07061986	A2	19950307	JP 1991-27273	19910221
	JP 3035745	B2	20000424		
	AT 139233	E	19960615	AT 1991-102513	19910221
	US 5284661	A	19940208	US 1993-47368	19930419
PRAI	JP 1990-42125	A	19900222		
	JP 1991-3958	A	19910117		
	US 1991-657051	B1	19910219		

OS MARPAT 115:232279
GI



I



II

AB Title compds. [I; R1, R2 = H, halo, cyano, NO2, acylamino, (substituted) hydrocarbyl; R3 = H, (substituted) alkyl, alkenyl, COX; X = H, alkoxy, OH, halo, amino; R4 = H, halo, NO2; R5 = residue capable of forming an anion or convertible to an anion; R6 = H, (substituted) alkyl, alkenyl; R7 = (substituted) hydrocarbyl; A = bond, spacer group; n = 1,2; W = CR3:CR6, NR7CO], were prepared Thus, Et 2-ethyl-4-hydroxythieno[2,3-b]pyridine-5-carboxylate, 4-(2'-cyanophenyl)benzyl chloride, and K2CO3 were stirred at 90° for 2 h to give 60% coupling product, which was stirred with NaN3 and NH4Cl in DMF at 110° to give 13% title compound II. Several I at 30 mg/kg orally in rats inhibited the pressor response of angiotensin II by ≥70%. Tablets were prepared containing II.

IT **137070-19-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of as intermediate for angiotensin II antagonist)

RN 137070-19-0 CAPLUS
CN Thieno[2,3-b]pyridine-5-methanol, 2-ethyl-4-hydroxy- (9CI) (CA INDEX NAME)



L32 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN

10634162

AN 1990:515227 CAPLUS
DN 113:115227
TI Polycyclic pyridines. Part 8. Synthesis of new primary, secondary and tertiary 3-aminothieno[2,3-b]pyridine-2-carboxamides by different pathways
AU Wagner, G.; Vieweg, H.; Leistner, S.; Boehm, N.; Krasselt, U.; Hanfeld, Vera; Prantz, J.; Grupe, Renate
CS Sekt. Biowiss., Karl-Marx-Univ., Leipzig, DDR-7010, Ger. Dem. Rep.
SO Pharmazie (1990), 45(2), 102-9
CODEN: PHARAT; ISSN: 0031-7144
DT Journal
LA German
OS CASREACT 113:115227
GI



I

AB The treatment of 2-thioxo-1,2-dihydropyridine-3-carbonitriles with ClCH2CO2NR1R3 (R1, R2 = H, Me, Et) gave 3-aminothieno[2,3-b]pyridinecarboxylic acid amides I [R1 = H, Et, Me; R2 = H, Et, Bu, cyclohexyl, CH2CH2OH, CH2CO2H; R1R2 = (CH2)5; R3 = Me, Ph, 4-BrC6H4, 3-pyridyl, CONH2, etc; R4 = H, Me, CH2C6H4(CN)-4; R5 = Me, C6H4Cl-4, Ph, C6H4Br-4, furyl, naphthyl, OH). Some of the compds. thus prepared, e.g. I (R1 = R2 = R4 = H, R3 = Me, R5 = Ph) and I (R1 = R4 = H, R2 = CH2CH2OH, R3 = R5 = Me) showed activity as antiallergics in the passive cutaneous anaphylaxis test in rats.

IT **119003-37-1P 119003-38-2P 119003-39-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 119003-37-1 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 119003-38-2 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4,6-dimethyl-5-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 119003-39-3 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-5-[(4-cyanophenyl)methyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)

10634162



L32 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1989:95203 CAPLUS
DN 110:95203
TI Preparation of 4-oxo-3,4-dihydropyrido[3',4',4,5]thieno[3,2-d]pyrimidine-2-carboxylates as drugs
IN Vieweg, Helmut; Leistner, Siegried; Wagner, Guenther; Krasselt, Uwe; Lohmann, Dieter; Laban, Gunter
PA Karl-Marx-Universitaet Leipzig, Ger. Dem. Rep.
SO Ger. (East), 4 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DD 258014	A1	19880706	DD 1987-300313	19870302
PRAI DD 1987-300313		19870302		

OS MARPAT 110:95203
GI



I II

AB The title compds. [I; R2 = C1-3 alkyl; R3 = Me, (substituted) alkyl; R4 = H, Me, (substituted) aryl], useful as potential drugs and intermediates, were prepared by cyclocondensation of aminothienopyrimidinecarboxamides II with R1O2CCO2R1 (R1 = C1-3 alkyl) in R2ONa/R2OH. II (R3 = Me, R4 = H, R5 = Ph) was heated briefly in MeOH/NaOMe; di-Et oxalate was added and the mixture was refluxed for 30 min to give 85% I (R2 = Et, R3 = Me, R4 = H, R5 = Ph).
IT **119003-37-1 119003-38-2 119003-39-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation of, with di-Et oxalate)
RN 119003-37-1 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 119003-38-2 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4,6-dimethyl-5-(phenylmethyl)- (9CI) (CA INDEX NAME)

10634162



RN 119003-39-3 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-5-[(4-cyanophenyl)methyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)



L32 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1981:550487 CAPLUS
DN 95:150487
TI A versatile new synthesis of quinolines and related fused pyridines. Part 7. The conversion of acetamidothiophenes into thienopyridines
AU Meth-Cohn, Otto; Narine, Brahma; Tarnowski, Brian
CS Dep. Chem. Appl. Chem., Univ. Salford, Salford, M5 4WT, UK
SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1981), (5), 1531-6
CODEN: JCPRB4; ISSN: 0300-922X
DT Journal
LA English
OS CASREACT 95:150487
GI



AB Reaction of DMF and POCl3 with 5-substituted 2-acetamidothiophenes (hot ClCH2CH2Cl) gave good yields of 2-acetamidothiophene-3-carboxaldehydes. E.g., benzothiophene I (R = H) reacted with DMF-POCl3 (1:1 mol, 15 min) to give 76% aldehyde I (R = CHO) and 12% thienopyridine II (R = H). Under similar conditions with 1:3 DMF-POCl3 for 1 h, 80% II (R = H) and 8% I (R = CHO) were formed. When POCl3 was used as solvent for the reaction (3:7 DMF-POCl3), 88% II (R = CHO) was formed. Thieno[3,2-b]- and -[3,4-b]pyridines were similarly prepared from 3-acetamido- and 2,5-dimethyl-3-acetamidothiophene, resp. The mechanisms of the reactions are discussed.
IT **68236-28-2P 68236-30-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by reaction of Vilsmeier reagent on acetamidothiophenes)
RN 68236-28-2 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxaldehyde, 6-chloro-2-methyl- (9CI) (CA INDEX NAME)



RN 68236-30-6 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxaldehyde, 6-chloro-2,3-dimethyl- (9CI) (CA INDEX NAME)



L32 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1978:597302 CAPLUS
DN 89:197302
TI A versatile new synthesis of quinolines, thienopyridines and related fused pyridines
AU Meth-Cohn, O.; Narine, Bramha
CS Dep. Chem. Appl. Chem., Univ. Salford, Salford, UK
SO Tetrahedron Letters (1978), (23), 2045-8
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English
OS CASREACT 89:197302
GI



AB Quinolines I [(R = H)(R1 = R2 = H, R3 = OMe, Me; R1 = H, OMe, R2 = R3 = OMe)] were prepared (59-73%) by Vilsmeier formylation of 3,4,5-R1R2R3C6H2NHAc with POCl3/DMF (3:1), whereas the corresponding formylquinolines I (R = CHO) were obtained (64-92%) using POCl3/DMF (7:3). Thienopyridines and their formyl derivs. were similarly prepared in good yield by Vilsmeier formylation of acetamidothiophenes. E.g., thienopyridine II was obtained (66%) by treatment of 2-acetamido-5-bromothiophene with POCl3/DMF (3:1).
IT **68236-28-2P 68236-30-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 68236-28-2 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxaldehyde, 6-chloro-2-methyl- (9CI) (CA INDEX NAME)



RN 68236-30-6 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxaldehyde, 6-chloro-2,3-dimethyl- (9CI) (CA INDEX NAME)

10634162



10634162

=> d 1-9 bib abs hitstr

L16 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:1006988 CAPLUS
DN 140:59632
TI Preparation of benzofused heteroaryl amide derivatives of **thienopyridines** as tyrosine kinase inhibitors useful against hyperproliferative disorders
IN Romines, William Henry, III; Kania, Robert Steven; Lou, Jihong; Collins, Michael Raymond; Cripps, Stephan James; He, Mingying; Zhou, Ru; Palmer, Cynthia Louise; Deal, Judith Gail
PA Pfizer Inc., USA
SO PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003106462	A1	20031224	WO 2003-IB2393	20030604
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004009965	A1	20040115	US 2003-460010	20030611
PRAI US 2002-389110P	P	20020614		

OS MARPAT 140:59632
GI



I



II

AB The invention relates to benzofused heteroaryl amide derivs. of **thienopyridines** (shown as I; variables defined below; e.g. II) and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compds., prodrugs, and metabolites. The invention also relates to pharmaceutical compns. containing I and to methods of treating hyperproliferative disorders in a mammal by administering I. Inhibitory activities of >200 examples of I are tabulated for a number of tyrosine kinases. Also, pharmacokinetics of 19 examples of I in mice and metabolism in human liver microsomes were analyzed. Although the methods of preparation are

not claimed, 140 example prepns. are included. For example, II was prepared in 5 steps starting from 3-methoxybenzenethiol and bromoacetaldehyde di-Et acetal and involving intermediates 1-[(2,2-diethoxyethyl)sulfanyl]-3-methoxybenzene, 6-methoxy-2-methylbenzo[b]thiophene, 6-methoxy-2-methylbenzo[b]thiophene-3-carboxylic acid methylamide, and 6-hydroxy-2-methylbenzo[b]thiophene-3-carboxylic acid methylamide; the last step comprises reaction of 7-chloro-2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridine and 6-hydroxy-2-methylbenzo[b]thiophene-3-carboxylic acid methylamide (40 %). For I: Y is NH, O, S, or CH2; Z is O, S, or N; R14 is a C1-C6 alkyl, C1-C6 alkylamino, C1-C6 alkylhydroxy, C3-C10 cycloalkylamino, or methylureido group; R15 and R17 = H, halo, or a C1-C6 alkyl group (un)substituted by ≥1 R5 groups. R16 is H or a C1-C6 alkyl group when Z is N, and R16 is absent when Z is O or S; R11 is H, C1-C6 alkyl, C3-C10 cycloalkyl, C(O)NR12R3, C(O)(C6-C10 aryl), (CH2)t(C6-C10 aryl), (CH2)t(5 to 10 membered heterocyclic), (CH2)tNR12R13, SO2NR12R13 or CO2R12. Each R5 = halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, C(O)R8, C(O)OR8, OC(O)R8, OC(O)OR8, NR6C(O)R7, C(O)NR6R7, NR6R7, OR9, SO2NR6R7, C1-C6 alkyl, C3-C10 cycloalkyl, C1-C6 alkylamino, (CH2)jO(CH2)qNR6R7, (CH2)tO(CH2)qOR9, (CH2)tOR9, S(O)j(C1-C6 alkyl), (CH2)t(C6-C10 aryl), (CH2)t(5 to 10 membered heterocyclic), C(O)(CH2)t(C6-C10 aryl), (CH2)tO(CH2)j(C6-C10 aryl), (CH2)tO(CH2)q(5 to 10 membered heterocyclic), C(O)(CH2)t(5 to 10 membered heterocyclic), (CH2)jNR7(CH2)qN R6R7, (CH2)jNR7CH2C(O)NR6R7, (CH2)jNR7(CH2)qNR9C(O)R8, (CH2)jNR7(CH2)tO(CH2)qOR9, (CH2)jNR7(CH2)qS(O)j(C1-C6 alkyl), (CH2)jNR7(CH2)tR6, SO2(CH2)t(C6-C10 aryl), and SO2(CH2)t(5 to 10 membered heterocyclic). Each R6 and R7 = H, OH, C1-C6 alkyl, C3-C10 cycloalkyl, (CH2)t(C6-C10 aryl), (CH2)t(5 to 10 membered heterocyclic), (CH2)tO(CH2)qOR9, (CH2)tCN(CH2)tOR9, (CH2)tCN(CH2)tR9 and (CH2)tOR9; each R8 = H, C1-C10 alkyl, C3-C10 cycloalkyl, (CH2)t(C6-C10 aryl), and (CH2)t(5 to 10 membered heterocyclic); t = 0-6; j = 0-2; q = 2-6; each R9 and R10 = H, OR6, C1-C6 alkyl, and C3-C10 cycloalkyl. Each R12 and R13 = H, C1-C6 alkyl, C3-C10 cycloalkyl, (CH2)t(C3-C10 cycloalkyl), (CH2)t(C6-C10 aryl), (CH2)t(5 to 10 membered heterocyclic), (CH2)tO(CH2)qOR9, and (CH2)tOR9; addnl. details including provisos are given in the claims.

IT **638216-89-4P 638217-02-4P 638217-10-4P 638217-22-8P**

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzofused heteroaryl amide derivs. of **thienopyridines** as tyrosine kinase inhibitors useful against hyperproliferative disorders)

RN 638216-89-4 CAPLUS

CN Benzo[b]thiophene-3-carboxamide, N,2-dimethyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638217-02-4 CAPLUS

CN Benzo[b]thiophene-3-carboxamide, N,2-dimethyl-6-[[2-(1-methyl-1H-pyrazol-5-yl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638217-10-4 CAPLUS
CN 3-Benzofurancarboxamide, N,2-dimethyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638217-22-8 CAPLUS
CN 1H-Indole-3-carboxamide, N,1,2-trimethyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



IT **638217-27-3P 638217-32-0P 638217-37-5P**
638217-41-1P 638217-45-5P 638217-47-7P
638217-48-8P 638217-56-8P 638217-59-1P
638217-60-4P 638217-61-5P 638217-63-7P
638217-67-1P 638217-77-3P 638217-79-5P
638217-81-9P 638217-83-1P 638217-88-6P
638217-93-3P 638217-95-5P 638218-00-5P
638218-01-6P 638218-04-9P 638218-12-9P
638218-15-2P 638218-21-0P 638218-22-1P
638218-29-8P 638218-36-7P 638218-39-0P
638218-46-9P 638218-52-7P 638218-56-1P
638218-59-4P 638218-84-5P 638219-42-8P
638219-44-0P 638219-45-1P 638219-66-6P
638219-68-8P 638219-73-5P 638219-88-2P
638220-05-0P 638220-07-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzofused heteroaryl amide derivs. of **thienopyridines** as tyrosine kinase inhibitors useful against hyperproliferative disorders)

RN 638217-27-3 CAPLUS
CN 1H-Indole-3-carboxamide, N-cyclopropyl-1,2-dimethyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638217-32-0 CAPLUS
CN 1H-Indole-3-carboxamide, N,1-dimethyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638217-37-5 CAPLUS
CN 1H-Indole-3-carboxamide, 6-[[2-[4-(hydroxymethyl)-2-thiazolyl]thieno[3,2-b]pyridin-7-yl]oxy]-N,1,2-trimethyl- (9CI) (CA INDEX NAME)



RN 638217-41-1 CAPLUS
CN Thieno[3,2-b]pyridine-2-carboxamide, N-[2-(dimethylamino)ethyl]-7-[[1,2-dimethyl-3-[(methylamino)carbonyl]-1H-indol-6-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 638217-45-5 CAPLUS
CN Thieno[3,2-b]pyridine-2-carboxamide, 7-[[1,2-dimethyl-3-[(methylamino)carbonyl]-1H-indol-6-yl]oxy]-N-(2-hydroxyethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 638217-47-7 CAPLUS
CN Thieno[3,2-b]pyridine-2-carboxamide, N-[3-(dimethylamino)propyl]-7-[[1,2-dimethyl-3-[(methylamino)carbonyl]-1H-indol-6-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 638217-48-8 CAPLUS
CN Thieno[3,2-b]pyridine-2-carboxamide, 7-[[1,2-dimethyl-3-[(methylamino)carbonyl]-1H-indol-6-yl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 638217-56-8 CAPLUS
CN 1H-Indole-3-carboxamide, N,1,2-trimethyl-6-[[2-(4-pyridinyl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638217-59-1 CAPLUS
CN 1H-Indole-3-carboxamide, N,1,2-trimethyl-6-[[2-(5-pyrimidinyl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638217-60-4 CAPLUS
CN 1H-Indole-3-carboxamide, 6-[[2-[4-(1-hydroxy-1-methylethyl)-2-thiazolyl]thieno[3,2-b]pyridin-7-yl]oxy]-N,1,2-trimethyl- (9CI) (CA INDEX NAME)



RN 638217-61-5 CAPLUS
CN 1H-Indole-3-carboxamide, N,1,2-trimethyl-6-[[2-(2-thiazolyl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638217-63-7 CAPLUS
CN 1H-Indole-3-carboxamide, N,1,2-trimethyl-6-[[2-(2-pyridinyl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638217-67-1 CAPLUS
CN 1H-Indole-3-carboxamide, N,1,2-trimethyl-6-[[2-[4-[(methylamino)carbonyl]-2-thiazolyl]thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638217-77-3 CAPLUS
CN 1H-Indole-3-carboxamide, 6-[[2-[4-(1-hydroxy-1-methylethyl)-2-oxazolyl]thieno[3,2-b]pyridin-7-yl]oxy]-N,1,2-trimethyl- (9CI) (CA INDEX NAME)



RN 638217-79-5 CAPLUS
CN 1H-Indole-3-carboxamide, 6-[[2-(5-methoxy-2-pyridinyl)thieno[3,2-b]pyridin-7-yl]oxy]-N,1,2-trimethyl- (9CI) (CA INDEX NAME)



RN 638217-81-9 CAPLUS
CN 1H-Indole-3-carboxamide, 6-[[2-(6-methoxy-2-pyridinyl)thieno[3,2-b]pyridin-7-yl]oxy]-N,1,2-trimethyl- (9CI) (CA INDEX NAME)



RN 638217-83-1 CAPLUS
CN 1H-Indole-3-carboxamide, N,1,2-trimethyl-6-[[2-(2-pyrimidinyl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638217-88-6 CAPLUS
CN 1H-Indole-3-carboxamide, 6-[[2-[6-[(dimethylamino)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxy]-N,1,2-trimethyl- (9CI) (CA INDEX NAME)



RN 638217-93-3 CAPLUS
CN 1H-Indole-3-carboxamide, N-(cyclopropylmethyl)-1,2-dimethyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638217-95-5 CAPLUS
CN 1H-Indole-3-carboxamide, N-(cyclopropylmethyl)-6-[[2-[4-(1-hydroxy-1-methylethyl)-2-thiazolyl]thieno[3,2-b]pyridin-7-yl]oxy]-1,2-dimethyl- (9CI) (CA INDEX NAME)



RN 638218-00-5 CAPLUS
CN 1H-Indole-3-carboxamide, 1,2-dimethyl-N-propyl-6-[[2-(2-thiazolyl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638218-01-6 CAPLUS
CN 1H-Indole-3-carboxamide, 1,2-dimethyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]-N-propyl- (9CI) (CA INDEX NAME)



RN 638218-04-9 CAPLUS
CN 1H-Indole-3-carboxamide, N-butyl-1,2-dimethyl-6-[[2-(2-thiazolyl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638218-12-9 CAPLUS

CN 1H-Indole-3-carboxamide, 1,2-dimethyl-N-(1-methylethyl)-6-[[2-(2-thiazolyl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638218-15-2 CAPLUS
CN 1H-Indole-3-carboxamide, 1,2-dimethyl-N-(2-methylpropyl)-6-[[2-(2-thiazolyl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638218-21-0 CAPLUS
CN 1H-Indole-3-carboxamide, 1,2-dimethyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]-N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 638218-22-1 CAPLUS
CN 1H-Indole-3-carboxamide, 1,2-dimethyl-N-2-pyridinyl-6-[[2-(2-thiazolyl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638218-29-8 CAPLUS
CN 1H-Indole-3-carboxamide, 1-ethyl-N,2-dimethyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638218-36-7 CAPLUS
CN 1H-Indole-3-carboxamide, 2-ethyl-N,1-dimethyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638218-39-0 CAPLUS
CN 1H-Indole-3-carboxamide, 2-chloro-6-[[2-[4-(1-hydroxy-1-methylethyl)-2-thiazolyl]thieno[3,2-b]pyridin-7-yl]oxy]-N,1-dimethyl- (9CI) (CA INDEX NAME)



RN 638218-46-9 CAPLUS
CN 1H-Indole-3-carboxamide, N,1-dimethyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 638218-52-7 CAPLUS
CN 3-Benzofurancarboxamide, 6-[[2-[4-(hydroxymethyl)-2-thiazolyl]thieno[3,2-b]pyridin-7-yl]oxy]-N,2-dimethyl- (9CI) (CA INDEX NAME)



RN 638218-56-1 CAPLUS
CN 3-Benzofurancarboxamide, 2-methyl-N-(1-methylethyl)-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638218-59-4 CAPLUS
CN 3-Benzofurancarboxamide, 2-methyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 638218-84-5 CAPLUS
CN 3-Benzofurancarboxamide, 2-ethyl-N-methyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638219-42-8 CAPLUS
CN Benzo[b]thiophene-3-carboxamide, N-cyclopropyl-2-methyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638219-44-0 CAPLUS
CN Benzo[b]thiophene-3-carboxamide, N-(3-hydroxypropyl)-2-methyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638219-45-1 CAPLUS
CN Benzo[b]thiophene-3-carboxamide, N-(cyclopropylmethyl)-2-methyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638219-66-6 CAPLUS

CN Benzo[b]thiophene-3-carboxamide, 6-[[2-[4-(hydroxymethyl)-2-thiazolyl]thieno[3,2-b]pyridin-7-yl]oxy]-N,2-dimethyl- (9CI) (CA INDEX NAME)



RN 638219-68-8 CAPLUS
CN Benzo[b]thiophene-3-carboxamide, N-cyclopropyl-6-[[2-[4-(hydroxymethyl)-2-thiazolyl]thieno[3,2-b]pyridin-7-yl]oxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 638219-73-5 CAPLUS
CN Benzo[b]thiophene-3-carboxamide, N-(cyclopropylmethyl)-6-[[2-[4-(hydroxymethyl)-2-thiazolyl]thieno[3,2-b]pyridin-7-yl]oxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 638219-88-2 CAPLUS
CN Benzo[b]thiophene-3-carboxamide, 2-ethyl-N-methyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638220-05-0 CAPLUS
CN Benzo[b]thiophene-3-carboxamide, 2-methyl-6-[(2-methylthieno[3,2-b]pyridin-7-yl)oxy]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 638220-07-2 CAPLUS
CN Benzo[b]thiophene-3-carboxamide, 2-methyl-6-[(2-methylthieno[3,2-b]pyridin-7-yl)oxy]-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



IT **638219-38-2P 638219-40-6P 638220-00-5P**

638220-02-7P 638220-03-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzofused heteroaryl amide derivs. of **thienopyridines** as tyrosine kinase inhibitors useful against hyperproliferative disorders)

RN 638219-38-2 CAPLUS
CN Benzo[b]thiophene-3-carboxylic acid, 2-methyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 638219-40-6 CAPLUS
CN Benzo[b]thiophene-3-carboxylic acid, 2-methyl-6-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 638220-00-5 CAPLUS
CN Benzo[b]thiophene-3-carboxylic acid, 2-methyl-6-[(2-methylthieno[3,2-b]pyridin-7-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 638220-02-7 CAPLUS
CN Benzo[b]thiophene-3-carboxylic acid, 2-methyl-6-[(2-methylthieno[3,2-b]pyridin-7-yl)oxy]- (9CI) (CA INDEX NAME)

10634162



RN 638220-03-8 CAPLUS
CN Benzo[b]thiophene-3-carbonyl chloride, 2-methyl-6-[(2-methylthieno[3,2-b]pyridin-7-yl)oxy]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:719486 CAPLUS
DN 139:246009
TI Preparation of **thienopyridinylaminoindolylureas** as antiangiogenic agents
IN Kania, Robert Steven; Romines, William Henry, III; Cripps, Stephan James; He, Mingying; Lou, Jihong; Zhou, Ru
PA Pfizer Inc., USA
SO PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003074529	A2	20030912	WO 2003-IB740	20030217
WO 2003074529	A3	20031224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004019065	A1	20040129	US 2003-371337	20030221
PRAI US 2002-360952P	P	20020301		

OS MARPAT 139:246009
GI



I



II

AB Title compds. I [X = CH, N; Y = Nh, O, S, CH2; Rl = H, (un)substituted alkyl, cycloalkyl, acyl, aryl, heterocyclic; R2 = H, (un)substituted alkyl, cycloalkyl, CONH2, aroyl, aryl, aralkyl, heterocyclic, heterocyclylalkyl, NH2, SO2NH2, CO2H] were prepared for use in treating hyperproliferative disorders in a mammal. Thus, the title compound II was prepared from the **thienopyridine** and aminoindolecarboxamide fragments and has Ki = 0.69 nM for inhibition of a VEGF-R2 construct.

IT **596793-65-6P 596793-66-7P 596793-68-9P 596793-70-3P 596793-71-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of **thienopyridinylaminoindolylureas** as antiangiogenic agents)

RN 596793-65-6 CAPLUS

CN 1H-Indole-1-carboxamide, 3a,7a-dihydro-5-[[2-[4-(1-hydroxy-1-methylethyl)-2-thiazolyl]thieno[3,2-b]pyridin-7-yl]oxy]-N,2-dimethyl- (9CI) (CA INDEX NAME)



RN 596793-66-7 CAPLUS

CN 1H-Indole-1-carboxamide, 4-fluoro-5-[[2-[4-(1-hydroxy-1-methylethyl)-2-thiazolyl]thieno[3,2-b]pyridin-7-yl]oxy]-N,2-dimethyl- (9CI) (CA INDEX NAME)



RN 596793-68-9 CAPLUS
CN 1H-Indole-1-carboxamide, 5-[[2-[4-(1-hydroxy-1-methylethyl)-2-thiazolyl]thieno[3,2-b]pyridin-7-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 596793-70-3 CAPLUS
CN 1H-Indole-1-carboxamide, 5-[[2-[4-(hydroxymethyl)-2-thiazolyl]thieno[3,2-b]pyridin-7-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 596793-71-4 CAPLUS
CN Thieno[3,2-b]pyridine-2-carboxamide, N-(2-hydroxyethyl)-N-methyl-7-[[2-methyl-1-[(methylamino)carbonyl]-1H-indol-5-yl]oxy]- (9CI) (CA INDEX NAME)



IT **481668-22-8 596793-67-8 596793-69-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of **thienopyridinylaminoindolylureas** as antiangiogenic agents)
RN 481668-22-8 CAPLUS
CN 4-Thiazolemethanol, α,α-dimethyl-2-[7-[(2-methyl-1H-indol-5-yl)oxy]thieno[3,2-b]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 596793-67-8 CAPLUS
CN 4-Thiazolemethanol, 2-[7-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]thieno[3,2-b]pyridin-2-yl]-α,α-dimethyl- (9CI) (CA INDEX NAME)



RN 596793-69-0 CAPLUS
CN 4-Thiazolemethanol, 2-[7-(1H-indol-5-yloxy)thieno[3,2-b]pyridin-2-yl]-α,α-dimethyl- (9CI) (CA INDEX NAME)



IT **596794-97-7P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of **thienopyridinylaminoindolylureas** as antiangiogenic agents)
RN 596794-97-7 CAPLUS
CN 1H-Indole-1-carboxamide, N,2-dimethyl-5-[[2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxy]- (9CI) (CA INDEX NAME)



L16 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:5724 CAPLUS
DN 138:73262
TI Preparation of **thienopyridines** and thienopyrimidines as anticancer agents
IN Marx, Matthew A.; Luzzio, Michael J.; Autry, Christopher L.
PA Pfizer Inc., USA
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003000194	A2	20030103	WO 2002-US19830	20020620
WO 2003000194	A3	20040129		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-299879P P 20010621
OS MARPAT 138:73262
GI



I



II

AB Title compds. [I, II; R1 = H, A, COA, (R5-substituted) Ar, het; A = alkyl; Het = heterocyclyl; Ar = aryl; R5 = halo, CN, NO2, OCF3, CF3, N3, COR8, CO2R8, O2CR8, OCO2R8, NR6COR7, NR6R7, OR9, SO2NR6R7, A, (CH2)tO(CH2)qOR9, (CH2)tOR9, S(O)jA, (CH2)tAr, (CH2)tHet, CO(CH2)tAr, (CH2)tO(CH2)jAr, (CH2)tO(CH2)qHet, CO(CH2)tHet, (CH2)jNR7(CH2)qNR6R7, (CH2)jNR7CH2C(O)NR6R7, (CH2)jNR7(CH2)tO(CH2)qOR9, (CH2)jNR7(CH2)qS(O)jA, (CH2)jNR7(CH2)tR6, SO2(CH2)tAr, SO2(CH2)tHet, etc.; j = 0-2; t = 0-6; q = 2-6; A, Ar, Het of R5 are optionally substituted by 1-3 halo, CN, NO2, CF3, N3, COR8, CO2R8, OCO2R8, NR6COR7, (CH2)tNR6R7, A, (CH2)tAr, (CH2)tHet, etc.; R6, R7 = H, A, (CH2)tAr, (CH2)tHet, (CH2)tO(CH2)qOR9, (CH2)tOR9; the A, Ar, Het of R6, R7 are optionally substituted by 1-3 halo, CN, NO2, CF3, N3, COR8, CO2R8, OCO2R8, NR9COR10, CONR9R10, NR9R10, A, (CH2)tAr, (CH2)tHet, (CH2)tOR9, etc.; R8 = H, A, (CH2)tAr, (CH2)tHet; t = 0-6; R9, R10 = H, Ar; R11 = H, A, CONR12R13, COAr, (CH2)tAr, (CH2)tHet, (CH2)tNR12R13, SO2NR12R13, CO2R12, A, COAr, (CH2)tAr, and (CH2)tHet are optionally substituted by 1-5 R5; R12, R13 = H, A, (CH2)t(cycloalkyl), (CH2)tAr, (CH2)tHet, (CH2)tO(CH2)qOR9, (CH2)tOR9, A, Ar, Het are

optionally substituted by 1-3 R5; R12R13N = (R5-substituted) azabicyclic, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, (thio)morpholinyl, (dihydro)isoquinolinyl], were prepared (no data). Thus, Cs2CO3, (3R)-(7-chlorothieno[3,2-b]pyridin-2-yl)(3-methoxypyrrolidin-1-yl)methanone (preparation given), and 2-methyl-1H-indol-5-ol (preparation given) in DMF were heated at 90° for 20 h to give (3R)-(3-methoxypyrrolidin-1-yl)[7-(2-methyl-1H-indol-5-yloxy)thieno[3,2-b]pyridin-2-yl]methanone.

IT **481668-20-6P 481668-21-7P 481668-22-8P**
481668-23-9P 481668-24-0P 481668-25-1P
481668-26-2P 481668-27-3P 481668-28-4P
481668-29-5P 481668-30-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of **thienopyridines** and thienopyrimidines as anticancer agents)

RN 481668-20-6 CAPLUS
CN Thieno[3,2-b]pyridine, 2-(1-methyl-1H-imidazol-5-yl)-7-[(2-methyl-1H-indol-5-yl)oxy]- (9CI) (CA INDEX NAME)



RN 481668-21-7 CAPLUS
CN Thieno[3,2-b]pyridine, 2-(1-methyl-1H-imidazol-2-yl)-7-[(2-methyl-1H-indol-5-yl)oxy]- (9CI) (CA INDEX NAME)



RN 481668-22-8 CAPLUS
CN 4-Thiazolemethanol, α,α-dimethyl-2-[7-[(2-methyl-1H-indol-5-yl)oxy]thieno[3,2-b]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 481668-23-9 CAPLUS
CN 4-Thiazolemethanol, α,α-dimethyl-2-[7-[(2-methyl-6-quinolinyl)oxy]thieno[3,2-b]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 481668-24-0 CAPLUS
CN 4-Thiazolemethanol, α,α-dimethyl-2-[7-(6-quinolinyloxy)thieno[3,2-b]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 481668-25-1 CAPLUS
CN 4-Thiazolemethanol, α,α-dimethyl-2-[7-[[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]oxy]thieno[3,2-b]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 481668-26-2 CAPLUS
CN Piperazine, 1-methyl-4-[[4-methyl-2-[7-[(2-methyl-1H-indol-5-yl)oxy]thieno[3,2-b]pyridin-2-yl]-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 481668-27-3 CAPLUS
CN Piperazine, 1-[[2-[7-[(3-cyano-2-methyl-1H-indol-5-yl)oxy]thieno[3,2-b]pyridin-2-yl]-4-methyl-5-thiazolyl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 481668-28-4 CAPLUS
CN Morpholine, 4-[[4-methyl-2-[7-[(5-phenyl-1H-pyrazol-3-yl)oxy]thieno[3,2-b]pyridin-2-yl]-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 481668-29-5 CAPLUS
CN Piperazine, 1-[[2-[7-[[5-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]thieno[3,2-b]pyridin-2-yl]-4-methyl-5-thiazolyl]carbonyl]-4-methyl- (9CI) (CA INDEX

NAME)

PAGE 1-A



PAGE 2-A



RN 481668-30-8 CAPLUS
CN Piperazine, 1-[[2-[7-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]thieno[3,2-b]pyridin-2-yl]-4-methyl-5-thiazolyl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A





L16 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:708828 CAPLUS
DN 129:330718
TI Furopyridine, **thienopyridine**, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission
IN Elliott, Richard L.; Ryther, Keith B.; Holladay, Mark W.; Wasciak, James T.; Daanen, Jerome F.; Lin, Nan-horng; Dart, Michael J.; He, Yun; Li, Yihong
PA Abbott Laboratories, USA
SO PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9846609	A1	19981022	WO 1998-US7128	19980410
	W: CA, JP, MX				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6001849	A	19991214	US 1997-834053	19970411
	EP 973777	A1	20000126	EP 1998-913418	19980410
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2001521523	T2	20011106	JP 1998-544055	19980410
	MX 9909239	A	20000331	MX 1999-9239	19991008
PRAI	US 1997-834053	A	19970411		
	US 1995-1619P	P	19950728		
	US 1996-679237	B2	19960723		
	WO 1998-US7128	W	19980410		

OS MARPAT 129:330718
GI



I

AB Heterocyclic ether compds. I [A = N heterocycle; X = O, S, NR3 where R3 = H, alkyl; m = 0-3; Y1, Y2, Y3 = N, CN and at least one must be N], which are useful in selectively controlling chemical synaptic transmission, were prepared E.g., reaction of 2-iodo-3-hydroxypyridine and N-2-propynylpyrrolidine in presence of bis(triphenylphosphine)palladium dichloride, CuI, and Et3N in DMF gave 72% 1-pyrrolidinylmethyl-2-furo[3,2-b]pyridine. The nicotinic acetylcholine receptor binding potencies of I were determined
IT **188056-43-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of furopyridine, **thienopyridine**, pyrrolopyridine, and related compds. useful in controlling chemical synaptic transmission)
RN 188056-43-1 CAPLUS
CN Thieno[3,2-b]pyridine, 5-methyl-2-(tetrahydro-1H-pyrrolizin-7a(5H)-yl)- (9CI) (CA INDEX NAME)



IT **188056-38-4P 188056-44-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of furopyridine, **thienopyridine**, pyrrolopyridine, and related compds. useful in controlling chemical synaptic transmission)
RN 188056-38-4 CAPLUS
CN Thieno[3,2-b]pyridine, 2-(tetrahydro-1H-pyrrolizin-7a(5H)-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188056-44-2 CAPLUS
CN Thieno[3,2-b]pyridine, 5-methyl-2-(tetrahydro-1H-pyrrolizin-7a(5H)-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT **188056-37-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of furopyridine, **thienopyridine**, pyrrolopyridine, and related compds. useful in controlling chemical synaptic transmission)
RN 188056-37-3 CAPLUS
CN Thieno[3,2-b]pyridine, 2-(tetrahydro-1H-pyrrolizin-7a(5H)-yl)- (9CI) (CA INDEX NAME)



10634162

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:134449 CAPLUS
DN 120:134449
TI Preparation of thieno[3,2-b]pyridine derivatives for the treatment of gastrointestinal disorders
IN Maruyama, Akira; Ogawa, Shigeru; Yamazaki, Satoshi; Tobe, Akihiro
PA Mitsubishi Kasei Corp., Japan
SO Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 560348	A1	19930915	EP 1993-103899	19930310
	EP 560348	B1	20020710		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 05310747	A2	19931122	JP 1993-22851	19930210
	JP 2699794	B2	19980119		
	AT 220403	E	20020715	AT 1993-103899	19930310
	PT 560348	T	20021129	PT 1993-103899	19930310
	ES 2179826	T3	20030201	ES 1993-103899	19930310
	CA 2091506	AA	19930913	CA 1993-2091506	19930311
	CA 2091506	C	20010529		
	US 5352685	A	19941004	US 1993-29551	19930311
PRAI	JP 1992-53864	A	19920312		

OS MARPAT 120:134449
GI



I

AB Title compds. I (Y = O, R3N wherein R3 = C1-6 alkyl; R1 = H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkylnyl, C3-8 cycloalkyl, C6-12 aryl, C7-18 aralkyl; R2 = H, C1-6 alkyl, halo, HO, C1-6 alkoxy, H2N, C1-6 alkyl, halo, C1-6 alkoxy, H2N, O2N, HS, C1-6 alkylthio; A = (substituted heterocyclyl) or a salt thereof, are prepared I are claimed also for treatment of anxiety and (or) neurosis and arrhythmia (no data). To DMF were added 4,7-dihydro-4-methyl-7-oxothieno[3,2-b]pyridine-6-carboxylic acid and N,N'-carbonyldiimidazole followed by (endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-ylamine in DMF to give endo-I (R1 = Me, R2 = H, Y = NH A = 8-methyl-8-azabicyclo[3.2.1]oct-3-yl) and converted to the HCl salt (II). In test for promoting action of gastric emptying, II or 1 mg/kg p.o showed 140%.

IT **152995-95-4P 152996-12-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for treatment of gastrointestinal disorders)

RN 152995-95-4 CAPLUS
CN Thieno[3,2-b]pyridine-6-carboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-7-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



RN 152996-12-8 CAPLUS
CN Thieno[3,2-b]pyridine-6-carboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-7-hydroxy-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **152996-02-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of drug for treatment of gastrointestinal disorders)
RN 152996-02-6 CAPLUS
CN Thieno[3,2-b]pyridine-6-carboxylic acid, 7-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1988:549506 CAPLUS
DN 109:149506
TI Preparation of **thienopyridinecarboxamide** derivatives as cardiovascular agents and formulations containing them
IN Davies, Roy Victor
PA Boots Co. PLC, UK
SO Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 269295	A1	19880601	EP 1987-309788	19871105
	EP 269295	B1	19910626		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	ZA 8708306	A	19880629	ZA 1987-8306	19871105
	AT 64736	E	19910715	AT 1987-309788	19871105
	ES 2038188	T3	19930716	ES 1987-309788	19871105
	FI 8705020	A	19880521	FI 1987-5020	19871113
	DK 8705998	A	19880521	DK 1987-5998	19871116
	IL 84505	A1	19901223	IL 1987-84505	19871117
	DD 282690	A5	19900919	DD 1987-309168	19871118
	NO 8704834	A	19880524	NO 1987-4834	19871119
	JP 63141984	A2	19880614	JP 1987-293042	19871119
	HU 47289	A2	19890228	HU 1987-5137	19871119
	HU 198060	B	19890728		
	US 4877793	A	19891031	US 1987-122394	19871119
	AU 8781440	A1	19880526	AU 1987-81440	19871120
	AU 599721	B2	19900726		
	CN 87107975	A	19880601	CN 1987-107975	19871120
	CN 1019491	B	19921216		

PL 149617 B1 19900331 PL 1987-268925 19871120
PRAI GB 1986-27698 19861120
EP 1987-309788 19871105
OS MARPAT 109:149506
GI



I

AB Title compds. I [R = lower alkyl; R1 = H, lower alkyl, alkoxy, halo, CF3, (substituted) Ph], useful as cardiovascular agents, were prepared Methylation of Et 7-hydroxythieno[3,2-b]pyridine-6-carboxylate, followed by amidation using aqueous NH3 gave I (R = Me, R1 = H) (II). At 30 mg/kg orally, II causes a min. significant reduction of blood pressure in spontaneously hypertensive rats. A tablet formulation containing II 100, lactose 100, starch 22, polyvinylpyrrolidone 10, and Mg stearate 3 weight parts was prepared

IT **116623-95-1 116643-24-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(alkylation of)

RN 116623-95-1 CAPLUS
CN Thieno[3,2-b]pyridine-6-carboxamide, 7-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



RN 116643-24-4 CAPLUS
CN Thieno[3,2-b]pyridine-6-carboxamide, 7-hydroxy-2-phenyl- (9CI) (CA INDEX NAME)



IT **116624-15-8P 116624-19-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of **thienopyridinone** cardiovascular agents)

RN 116624-15-8 CAPLUS
CN Thieno[3,2-b]pyridine-6-carboxylic acid, 7-hydroxy-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 116624-19-2 CAPLUS

10634162

CN Thieno[3,2-b]pyridine-6-carboxylic acid, 7-hydroxy-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1986:608886 CAPLUS
DN 105:208886
TI Imidazolylthienopyridine derivatives as herbicides
IN Numata, Tatsuo; Hatanaka, Masataka; Watanabe, Junichi; Igai, Takashi; Nawamaki, Tsutomu
PA Nissan Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 26 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61109790	A2	19860528	JP 1984-230874	19841031

PRAI JP 1984-230874 19841031
OS CASREACT 105:208886
GI



I



II

AB The title compds. [I and II; R = Q; R1 = alkyl; R2 = (cyclo)alkyl or R1R2 = (un)substituted alkylene; R3, R4 = H, halo, alkyl, (un)substituted Ph, etc. or R3R4 = (un)substituted alkylene; R5 = H, alkyl, etc.; n = 0,1] were prepared Thus, anhydride formation of I (R = CO2H; R3 = R5 = H; R4 = Me; n=0) in Ac2O at 100° followed by the reaction of the resulting I (RR5 = CO; R3 = H; R4 = Me; n = O) with H2NCMe(CONH2)CHMe2 gave I [R = CONHCMe(CONH2)CHMe2; R3 = R5 = H; R4 = Me; n = O) whose cyclization in NaOH/H2O at 70-80° for 4 h gave, after acidification, I (R = Q; R1 = R4 = Me; R2 = CHMe2; R3 = H; n = O). The prepared I and II at 0.8-3.2 g/are were effective against common weeds, e.g., Echinochloa crus-galli.

IT **105126-30-5P 105126-31-6P 105126-33-8P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide)

RN 105126-30-5 CAPLUS
CN Thieno[3,2-b]pyridine-6-carboxylic acid, 5-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 105126-31-6 CAPLUS
CN Thieno[3,2-b]pyridine-6-carboxylic acid, 5-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 105126-33-8 CAPLUS
CN Thieno[3,2-b]pyridine-6-carboxylic acid, 5-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-2,3-dimethyl- (9CI) (CA INDEX NAME)



L16 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1986:460612 CAPLUS
DN 105:60612
TI (Tetrazolyl)**thienopyridinones**
IN Wright, Terry L.
PA Merrell Dow Pharmaceuticals, Inc., USA
SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 177924	A1	19860416	EP 1985-112689	19851007
	EP 177924	B1	19900221		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4593099	A	19860603	US 1984-659397	19841010
	CA 1293257	A1	19911217	CA 1985-492239	19851004
	AT 50449	E	19900315	AT 1985-112689	19851007
	JP 61112081	A2	19860530	JP 1985-223880	19851009
	JP 06041469	B4	19940601		
PRAI	US 1984-659397		19841010		
	EP 1985-112689		19851007		

OS CASREACT 105:60612
GI For diagram(s), see printed CA Issue.
AB Title compds. I (Z forms a fused thieno which can contain 1 or 2 Me groups) were prepared, and they showed anti-allergic activity. **Thienopyridinone** derivative II (R1 = cyano), which was prepared from 3-acetamidothiophene in a series of reactions, was treated with NaN3 to give II (R1 = 1H-tetrazol-5-yl).
IT **102902-34-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 102902-34-1 CAPLUS
CN Thieno[3,2-b]pyridine-5-carbonitrile, 6-chloro-2-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1982:616153 CAPLUS
DN 97:216153
TI Thieno[3,2-b]pyridinecarboxylic acid derivatives
PA Kanebo, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 57116077	A2	19820719	JP 1981-3457	19810112
PRAI	JP 1981-3457		19810112		

OS CASREACT 97:216153
GI



I



III



IV



V

AB Title derivs. I [4-pyridyl, R = Et (II); 4-pyridyl, R = H2C:CH; 3-pyridyl, R = Et] useful as bactericides (data given) were prepared Thus, heating 21.6 g III with 21.3 g H2C:C(CO2Et)2 in DMF 2 h at 150° gave 21.2 g IV, which (10 g) was stirred with 58 g Et polyphosphate 2.5 h at 120° to give 3.1 g V. Stirring 0.99 g V with 0.25 mL EtI in DMF in the presence of 0.16 g 50 % oily NaH 3 h at 70° gave 0.36 g Et ester of II. Refluxing 1.4 g the ester in 10% aqueous KOH 1.5 h gave 0.8 g II.

IT **83739-52-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and dehydrogenation of)

RN 83739-52-0 CAPLUS
CN Thieno[3,2-b]pyridine-6-carboxylic acid, 7-hydroxy-2-(4-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)